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Hyperammonemia has been associated with intracranial hypertension and mortality in patients with acute liver failure
(ALF). We evaluated the effect of renal replacement therapy (RRT) on serum ammonia level and outcomes in ALF. This
was a multicenter cohort study of consecutive ALF patients from the United States ALF Study Group registry between
January 1998 and December 2016. First, we studied the association of ammonia with hepatic encephalopathy (HE) and
21-day transplant-free survival (TFS; n 5 1,186). Second, we studied the effect of RRT on ammonia for the first 3 days
post study admission (n 5 340) and on 21-day TFS (n 5 1,186). Higher admission (n 5 1,186) median ammonia level
was associated with grade 3-4 HE (116 vs. 83 lmol/L) and mortality at day 21 attributed to neurological (181 vs. 90
lmol/L) and all causes (114 vs. 83 lmol/L; P < 0.001 for all). Among 340 patients with serial ammonia levels, 61 (18%)
were on continuous RRT (CRRT), 59 (17%) were on intermittent RRT (IRRT), and 220 (65%) received no RRT for the
first 2 days. From days 1 to 3, median ammonia decreased by 38%, 23%, and 19% with CRRT, IRRT, and no RRT,
respectively. Comparing to no RRT use, whereas ammonia reduction with CRRT was significant (P 5 0.007), with
IRRT it was not (P 5 0.75). After adjusting for year of enrollment, age, etiology, and disease severity, whereas CRRT
(odds ratio [OR], 0.47 [95% confidence interval fCIg, 0.26-0.82]) was associated with reduction in 21-day transplant-free
all-cause mortality, IRRT (OR, 1.68 [95% CI, 1.04-2.72]) was associated with an increase. Conclusion: In a large cohort of
ALF patients, hyperammonemia was associated with high-grade HE and worse 21-day TFS. CRRT was associated with a
reduction in serum ammonia level and improvement of 21-day TFS. (HEPATOLOGY 2018;67:711-720).
I
n acute liver failure (ALF), hepatocyte loss results in
reduced ammonia detoxification and hyperammone-
mia, both through reductions in urea cycle (conversion
to urea) and glutamine metabolism. With the frequent
coexistent acute kidney injury in ALF, reduced renal
ammonia excretion further worsens hyperammonemia.(1)
In ALF, hyperammonemia has been associated with
hepatic encephalopathy (HE), cerebral edema, intra-
cranial hypertension, and mortality from cerebral her-
niation.(2,3) The mechanisms by which ammonia
causes this neurological dysfunction are still not fully
understood. Whether by direct effect or after
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metabolization to glutamine in the astrocytes, ammo-
nia may contribute to local altered neurotransmitter
action, impaired mitochondrial function, and increased
oxidative stress, which may lead to downstream astro-
cytic swelling and cerebral edema.(4,5)
In ALF, current ammonia-lowering strategies rely
mainly on supportive treatment for organ failures.(6)
However, the use of extracorporeal devices has been
proposed to reduce serum ammonia level.(7,8) Recently,
in a small cohort study, patients with acute or chronic
liver dysfunction and hyperammonemia on renal
replacement therapy (RRT) for 24 hours showed a sig-
nificant reduction in serum ammonia level.(9)
To date, no formal study has evaluated RRT effect
on serum ammonia level in patients with ALF. In this
context, we hypothesized that RRT use would signifi-
cantly reduce serum ammonia level in comparison to
no RRT support. Therefore, we aimed to: determine
the association of serum ammonia level and patients’
clinical outcomes; evaluate the effect of RRT on serum
ammonia level throughout a 3-day period; and assess




We performed a retrospective cohort study of
patients with ALF enrolled in the United States ALF
Study Group (US-ALFSG) prospective registry bet-
ween January 1998 and August 2016. Patients not ful-
filling criteria for ALF (see operational definitions) or
with lack of data on serum ammonia level or RRT sta-
tus at study admission were initially excluded (Sup-
porting Fig. S1; original cohort, n51,186). For the
analysis of ammonia dynamics between days 1 and 3
post study admission, patients lacking data on serum
ammonia level or RRT status for either of these days
were excluded (n 5 340). Within this subset of
patients, a subanalysis was performed following exclu-
sion of the 16 patients enrolled as well in the US-
ALFSG STOP-ALF trial designed to determine
safety and tolerability of ornithine phenylacetate
(OPA), a putative ammonia lowering agent, given that
the use of OPA might confound the results.
The study’s protocol has been approved by the insti-
tutional review board or health research ethics board at
all enrolling sites (tertiary liver transplantation referral
centers) within the US-ALFSG (see Appendix).
Informed consent was obtained from next of kin for all
enrolled patients because were unable to provide it on
their own because of HE. All research procedures were
conducted according to the principles of the Declara-
tion of Helsinki.(10)
OPERATIONAL DEFINITIONS
ALF was defined using the following criteria: (1)
HE of any degree; (2) international normalized ratio
(INR) 1.5; (3) acute illness onset <26 weeks; and (4)
no evidence of cirrhosis. Given the reported similar
clinical impact, we considered both arterial (n 5 509
at study admission) and venous (n 5 677 at study
admission) ammonia levels.(11) RRT included inter-
mittent (IRRT), such as hemodialysis or sustained
low-efficiency dialysis, and continuous (CRRT) mod-
alities.(12) To avoid understating IRRT efficiency and
facilitate comparisons with CRRT, the analysis of
ammonia dynamics between days 1 and 3 post study
admission considered RRT use on days 1 and 2 (up to
48 hours). The use of RRT within the US-ALFSG is
not protocolized; therefore, indications, modality,
replacement fluid, anticoagulation, treatment dose, and
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timings for initiation and suspension of RRT were
based on clinical judgment at each enrolling site.
EXPOSURES AND ENDPOINTS
The US-ALFSG registry data repository (Medical
University of South Carolina, Charleston, SC) con-
tains demographic, clinical, and outcome data. Data
were retrieved on the following baseline characteristics
of patients with ALF: age; sex; race; etiology; HE
(West Haven criteria); organ support requirements
(invasive mechanical ventilation [IMV], vasopressors,
and RRT); laboratory serum profile (ammonia,
INR, bilirubin, alanine aminotransferase [ALT], creat-
inine, potassium, phosphate, pH, and lactate); n-
acetylcysteine use; and clinical outcomes (21-day post
study admission transplant-free survival [TFS], overall
survival, and orthotopic liver transplantation [OLT]).
The primary endpoint for this study was the differ-
ence in serum ammonia level between days 1 and 3
post study admission. The secondary endpoint was 21-
day post study admission TFS.
Based on previous literature, we could expect a
reduction of median serum ammonia level of 22% after
24 hours of CRRT.(9) Accordingly, to detect a differ-
ence of 15% in median serum ammonia level between
RRT and no RRT use, with 90% power and a cutoff
for statistical significance of 0.05, we would require a
sample with at least 110 patients in each arm.(13)
STATISTICAL ANALYSIS
Categorical variables were presented as proportions
and continuous variables as median and interquartile
ranges (IQRs). For the baseline characteristics, com-
parisons for independent samples were performed with
chi-square test or Mann-Whitney test. For the serial
ammonia analysis, comparisons for related samples
were done with the Friedman test. For the baseline
characteristics and serial ammonia analyses, missing
data were 3% and 5%, respectively; therefore, no multi-
ple imputations were performed.
The study of associations with 21-day post study
admission transplant-free all-cause mortality was done
with logistic regression. For multivariate analysis, cova-
riates were initially chosen based on clinical relevance
or P < 0.10 on univariate comparisons, including: year
of admission, age, etiology, HE, IMV, vasopressors,
RRT, ammonia, bilirubin, creatinine, potassium, phos-
phate, pH, lactate, and n-acetylcysteine. Final models
were derived based on a step-wise backward
elimination process. Collinearity was evaluated and
avoided where appropriate. Models’ performance was
assessed by chi-square test and area under the receiver
operating characteristic curve (AUC). All comparisons
considered a threshold for statistical significance of
0.05. Statistical analysis was performed using IBM





A total of 1,186 consecutive patients with ALF and
complete data on ammonia level and RRT status at
study admission were identified within the US-
ALFSG registry between January 1998 and August
2016 (Supporting Fig. S1).
Median (IQR) age was 39 (29-52) years, and
819 patients (69%) were females. Acetaminophen
(APAP)-related ALF occurred in 593 (50%) patients.
All etiologies are specified in Supporting Fig. S2.
At study admission, 600 (51%) patients developed
grade 3-4 HE. IMV, vasopressors, and RRT were
required in 632 (56%), 299 (25%), and 314 (26%)
patients, respectively. Median (IQR) INR, ammonia,
creatinine, and lactate levels were 2.8 (2.1-4.2), 97
(63-157) lmol/L, 1.70 (0.90-3.16) mg/dL, and 4.1
(2.4-7.7) mmol/L, respectively. All baseline character-




In the original cohort, 1,051 patients had complete
data on both OLT (1,169 patients if OLT status only)
and survival (1,067 patients if survival status only) sta-
tus at 21 days post study admission. Among them, 224
(21%) were transplanted and 493 (60% of nontrans-
planted patients) survived without OLT at 21 days
post study admission (Table 1). The causes of mortal-
ity are specified in Supporting Fig. S3.
Median ammonia level at study admission was sig-
nificantly greater for patients with grade 3-4 versus
grade 1-2 HE (116 vs. 83 lmol/L) or who died from
neurological cause versus all others (181 vs. 90 lmol/
L) or any cause versus alive (114 vs. 83 lmol/L) at 21
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days post study admission (Table 2; P < 0.001 for all
comparisons).
The ammonia cutoffs 100, 150, and 200
lmol/L at study admission were associated with 21-
day neurological mortality (without OLT) with a sen-
sitivity of 77%, 58%, and 42% respectively, and a spe-
cificity of 55%, 76%, and 87%, respectively (AUC of




Patients on RRT at study admission had signifi-
cantly greater proportions of grade 3-4 HE (71% vs.
43%) and requirement for IMV (81% vs. 43%) and
vasopressors (56% vs. 14%; P < 0.001 for all compari-
sons). These patients had also significantly greater
admission median ammonia (110 vs. 95 lmol/L), cre-
atinine (2.80 vs.1.34 mg/dL), phosphate (3.8 vs. 2.8
mmol/dL), and lactate (6.3 vs. 3.5 mmol/L) levels
(P < 0.001 for all comparisons). Furthermore, they
had significantly lower 21-day post study admission
TFS (47% vs. 65%; P < 0.001). Stratification of all
baseline characteristics of the original cohort by RRT
requirement at study admission is depicted in Table 1.
Patients admitted during the 2007-2016 period
were significantly more likely to be on RRT on day 1
than the ones admitted in the 1998-2006 period (62%
vs. 38%; P 5 0.005). At study admission, being on
IRRT was significantly more frequent in the 1998-
2006 period (48% vs. 52%; P 5 0.027), whereas being
on CRRT was more common in the 2007-2016 period
(83% vs. 17%; P < 0.001).
Among patients on RRT at study admission (n 5
314), the ones on CRRT (n 5 119) had significantly
greater proportion of requirement for vasopressors
(64% vs. 51%; P 5 0.029) than the ones on IRRT
(n 5 195). Patients on CRRT had also significantly
greater admission median INR (3.2 vs. 2.7; P 5
TABLE 1. Baseline Characteristics of Patients With ALF at Study Admission (n 5 1,186)




RRT on Day 1
(n 5 314)
No RRT on Day 1
(n 5 872) P Value*
Age 1,186 39 (29-52) 38 (28-50) 40 (29-52) 0.15
Sex (female) 1,186 819 (69%) 212 (68%) 607 (70%) 0.49
Race 1,186 0.12
White 878 (74%) 234 (75%) 644 (74%)
Black 184 (16%) 40 (13%) 144 (17%)
Other 124 (11%) 40 (13%) 84 (10%)
Etiology (APAP) 1,186 593 (50%) 169 (54%) 424 (49%) 0.11
HE grades 3-4 1,186 600 (51%) 223 (71%) 377 (43%) <0.001
Organ support
Mechanical ventilation 1,186 632 (53%) 254 (81%) 378 (43%) <0.001
Vasopressors 1,186 299 (25%) 176 (56%) 123 (14%) <0.001
Biochemistry (admission)
Ammonia (lmol/L) 1,186 97 (63-157) 110 (68-185) 95 (61-144) <0.001
INR 1,186 2.8 (2.1-4.2) 2.9 (2.1-4.3) 2.7 (2.1-4.1) 0.38
Bilirubin (mg/dL) 1,178 6.6 (3.4-17.4) 6.2 (3.7-10.8) 6.8 (3.3-19.7) 0.07
ALT (U/L) 1,176 2,247 (734-4,718) 2,600 (852-4,798) 2,108 (699-4,645) 0.18
Creatinine (mg/dL) 1,180 1.70 (0.90-3.16) 2.80 (1.72-4.12) 1.34 (0.80-2.60) <0.001
Phosphate (mmol/dL) 1,062 3.0 (2.0-4.5) 3.8 (2.5-5.6) 2.8 (1.9-4.0) <0.001
pH 977 7.42 (7.35-7.48) 7.40 (7.32-7.46) 7.43 (7.37-7.48) <0.001
Lactate (mmol/L) 739 4.1 (2.4-7.7) 6.3 (3.4-10.3) 3.5 (2.1-5.9) <0.001
NAC 1,186 783 (66%) 220 (70%) 563 (65%) 0.08
21-day OLT 1,169 259 (22%) 71 (23%) 188 (22%) 0.74
21-day overall mortality 1,067 359 (34%) 129 (44%) 230 (30%) <0.001
21-day transplant-free survival 827 493 (60%) 108 (47%) 385 (65%) <0.001
*Mann-Whitney U or chi-square tests. a 5 0.05.
Abbreviation: NAC, N-acetylcysteine.
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0.003) and lower admission median creatinine (2.3 vs.
3.2 mg/dL; P < 0.001), phosphate (4.2 vs. 3.3 mmol/
dL; P 5 0.034), and lactate (6.2 vs. 7.9 mmol/L; P 5
0.025) levels. However, there was no significant differ-
ence on admission median ammonia level (133 vs.
102 lmol/L; P 5 0.052). All baseline characteristics of
patients on RRT at study admission stratified by type
of RRT (CRRT vs. IRRT) are depicted in Supporting
Table S1.
SERUM AMMONIA DYNAMICS
BETWEEN DAYS 1 AND 3 POST
STUDY ADMISSION
A total of 340 patients with ALF and complete data
on ammonia level and RRT status between days 1 and
3 post study admission were identified within the US-
ALFSG registry between January 1998 and August
2016 (Supporting Fig. S1).
Between days 1 and 3 post study admission, a maxi-
mum of 63 (19%), 56 (16%), and 221 (65%) patients
were on IRRT, CRRT, or no RRT at all at any day,
respectively. During this 3-day period, median (day 1
vs. day 3) ammonia (100 vs. 81 lmol/L), INR (3.0 vs.
2.0), creatinine (1.50 vs. 1.49 mg/dL), lactate (4.2 vs.
2.8 mmol/L), and bilirubin (5.3 vs. 7.8 mg/dL) levels
varied significantly (P < 0.001 for all day 1 vs. day 2
vs. day 3 comparisons). Patients’ RRT status and bio-
chemical changes between days 1 and 3 post study
admission are depicted in Table 3.
Between days 1 and 3 post study admission, the
reduction of median ammonia level differed with the
TABLE 3. Serial Characteristics of Patients With ALF From Days 1 to 3 Post Study Admission (n 5 340)
n Day 1 n Day 2 n Day 3 P Value*
RRT (on each day)
Overall 340 91 (27%) 340 112 (33%) 340 119 (35%) <0.001
CRRT 340 45 (13%) 340 56 (17%) 340 56 (17%) 0.028
IRRT 340 46 (14%) 340 56 (17%) 340 63 (19%) 0.001
HE grades 3-4 340 170 (50%) 321 179 (56%) 340 173 (51%) 0.029
Ammonia (lmol/L)
Overall 340 100 (70-157) 340 88 (64-127) 340 81 (52-112) <0.001
CRRT
(on days 1-2)
61 140 (79-192) 61 103 (78-172) 61 87 (66-125) <0.001
IRRT
(on days 1-2)
59 98 (69-133) 59 89 (63-130) 59 75 (44-116) 0.066
No RRT
(on days 1-2)
220 97 (68-145) 220 82 (61-119) 220 79 (50-105) <0.001
INR 340 3.0 (2.1-4.3) 336 2.4 (1.8-3.4) 331 2.0 (1.6-3.0) <0.001
Bilirubin (mg/dL) 337 5.3 (3.0-15.4) 333 6.3 (3.4-14.4) 332 7.8 (4.0-16.5) <0.001
Creatinine (mg/dL) 337 1.50 (0.90-2.80) 340 1.54 (0.80-2.79) 336 1.49 (0.80-2.44) <0.001
Lactate (mmol/L) 242 4.2 (2.5-8.0) 193 3.1 (2.0-6.1) 166 2.8 (1.7-5.8) <0.001
a 5 0.05.
*Friedman test (comparisons of day 1 vs. day 2 vs. day 3).
TABLE 2. Association of Ammonia Level With Clinical Outcomes of Patients With ALF (n 5 1,186)
Ammonia (lmol/L) (n 5 1,186)
[median (IQR)]
OR (95% CI)* P Value†
Yes No
HE grades 3-4 at study admission
(n 5 1,186)
116 (77-186) 83 (54-123) 1.006 (1.005-1.008) <0.001
21-day transplant-free neurological mortality
(n 5 613)
181 (102-257) 90 (57-146) 1.004 (1.003-1.006) <0.001
21-day transplant-free all-cause mortality
(n 5 827)
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type of RRT used during days 1 and 2 (Fig. 1): 28.1%
with any type of RRT (120 patients); 23.4% with
IRRT (any of days 1 and 2 but without CRRT—59
patients); 37.9% with CRRT (any of days 1 and 2 with
or without IRRT—61 patients); and 18.6% without
any RRT at all (220 patients). Whereas median
ammonia level reduction with CRRT was significantly
greater than without RRT use (P 5 0.007), with
IRRT it was not (P 5 0.75).
The variations in ammonia dynamics between days
1 and 3 post study admission with each type of RRT
stratified by etiology of ALF (APAP vs. other etiolo-
gies) are depicted in Supporting Table S2. Ammonia-
level reduction with CRRT was greater than no RRT
use for both etiology subgroups (38.6% vs. 21.6% for
APAP and 38.5% vs. 11.3% other etiologies), but did
not reach statistical significance probably attributed to
lower number of patients in each treatment arm (P 5
0.085 and P 5 0.054, respectively).
Ammonia dynamics between days 1 and 3 post
study admission were similar within the subgroup of
patients with ALF following exclusion of the 16
patients included in the US-ALFSG trial on the
impact of OPA for HE management in ALF (Sup-
porting Table S3). Therefore, the overall results were
not affected by OPA therapy.
ASSOCIATION OF RRT WITH
PATIENTS’ SURVIVAL
We derived three models to better assess the effect
of RRT (overall, IRRT, or CRRT) on 21-day post
study admission transplant-free all-cause mortality
(Table 4). After adjusting for year of admission (2007-
2016 vs. 1998-2006), age, etiology (APAP vs. non-
APAP), and disease severity (requirement for IMV,
vasopressors, INR, creatinine, and ammonia levels),
RRT use on day 1 was significantly associated with
lower 21-day post study admission transplant-free all-
cause mortality (adjusted odds ratio [aOR] of 0.47
[95% CI, 0.26-0.82]). Conversely, IRRT use on day 1
was significantly associated with greater 21-day post
study admission transplant-free all-cause mortality
(aOR of 1.68 [95% CI, 1.04-2.72]). The performance






Using a large cohort of patients with ALF, we have
shown that the degree of hyperammonemia was signif-
icantly associated with worse clinical outcomes, includ-
ing high-grade (3-4) HE and lower 21-day post study
admission TFS (P < 0.001 for both comparisons).
These findings are consistent with previous reports
suggesting the use of hyperammonemia as a severity
marker in ALF.(14,15)
Patients with ALF on RRT at study admission had
greater disease severity, especially in terms of extrahe-
patic organ failures: More patients demonstrated high-
grade HE and requirement for IMV and vasopressors,
as well as greater median ammonia, creatinine, and lac-
tate levels (P < 0.001 for all comparisons). Further-
more, these patients had lower 21-day post study
admission TFS (47% vs. 65%; P < 0.001). These find-
ings likely reflect the choice of RRT for patients with
the most severe clinical course of ALF, including acute
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FIG. 1. (A,B) Renal replacement therapy on days 1 and 2 and
median serum ammonia level (lmol/L) between days 1 and 3
post study admission (n 5 340).
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kidney injury and metabolic acidosis, the most com-
mon clinical context for RRT initiation.(12,16,17)
In addition, RRT use in patients with ALF
increased greatly between the 1998-2006 and 2007-
2016 periods (38% vs. 62%; P 5 0.005), especially
CRRT utilization (17% vs. 83%; P < 0.001). These
findings likely reflect the increasing use of RRT in
clinical practice to treat acute kidney injury in general
patients, including those with liver dysfunction. Previ-
ous studies have shown a significant improvement in
survival and renal function recovery with the timely use
of RRT, especially in the most severe cases of acute
kidney injury.(18,19)
We have also found that RRT use on days 1 and 2
post study admission was associated with a trend
toward reduced median serum ammonia level between
days 1 and 3 post study admission when compared
with no RRT utilization (28.1% vs. 18.6%; P 5
0.051). Whereas such a reduction was significant with
CRRT (37.9% vs. 18.6%; P 5 0.007), with IRRT it
was not (23.4% vs. 18.6%; P 5 0.75).
This study provides evidence of CRRT capacity to
reduce serum ammonia level in ALF in comparison
with IRRT and no RRT use. In a small cohort study
including patients with acute or chronic liver dysfunc-
tion and hyperammonemia (n 5 24), Slack et al.
reported an overall reduction of 22% on median serum
ammonia level with 24 hours’ use of CRRT.(9) In our
cohort, the overall reduction in median serum ammo-
nia level with CRRT was greater (37.9%). This differ-
ence may be partially explained by the type of patients
included in our cohort (only ALF) and the longer
course of CRRT utilized (up to 48 hours after study
admission). Furthermore, other factors have been
described to contribute to CRRT efficiency in this
context, for example: pH, blood and replacement fluid
flow rates, filter surface area and clotting, and treat-
ment interruptions.(7,9,20) Median pH was found to be
within normal range in patients with and without
RRT at study admission (7.40 vs. 7.43; P < 0.001),
therefore it unlikely affected ammonia dynamics.
However, data regarding other such technical aspects
of RRT were not recorded in the US-ALFSG registry
(see Limitations).
Finally, we showed that CRRT use at day 1 was
independently associated (after adjusting for year of
admission, age, etiology, and disease severity) with
lower 21-day post study admission transplant-free all-
cause mortality (aOR of 0.47). Conversely, IRRT was
independently associated with higher 21-day post
study admission transplant-free all-cause mortality
(aOR of 1.68).
In a study designed to study the impact of high-
volume plasma exchange on hospital survival of
patients with ALF, Larsen et al. reported that median
serum ammonia levels decreased significantly more
rapidly with high-volume plasma exchange than with
standard medical treatment (29.7% vs. 1.5% between
days 1 and 3 post study admission).(21) Furthermore,
high-volume plasma exchange significantly improved
hospital TFS (58.7% vs. 47.8%). The plasma exchange
protocol used in this study consisted of replacing 8-12
TABLE 4. Association of Renal Replacement Therapy Use on Day 1 With 21-Day Post Study Admission Transplant-Free
All-Cause Mortality for Patients With ALF (n 5 1,186)
Model 1* Model 2† Model 3‡
aOR (95% CI) P Value§ aOR (95% CI) P Value§ aOR (95% CI) P Value§
Year of admission (2007-2016
vs. 1998-2006)
0.48 (0.34-0.68) <0.001 0.49 (0.34-0.69) <0.001 0.52 (0.37-0.75) <0.001
Age 1.04 (1.03-1.05) <0.001 1.04 (1.03-1.05) <0.001 1.04 (1.02-1.05) <0.001
APAP 0.28 (0.20-0.41) <0.001 0.28 (0.20-0.40) <0.001 0.27 (0.19-0.40) <0.001
IMV 2.34 (1.60-3.42) <0.001 2.25 (1.54-3.29) <0.001 2.41 (1.65-3.52) <0.001
Vasopressors 3.67 (2.38-5.67) <0.001 3.40 (2.25-5.12) <0.001 4.34 (2.82-6.69) <0.001
INR 1.28 (1.17-1.40) <0.001 1.29 (1.18-1.41) <0.001 1.28 (1.18-1.40) <0.001
Creatinine (mg/dL) 1.10 (1.00-1.21) 0.041 1.07 (0.97-1.18) 0.16 1.11 (1.01-1.21) 0.032
Ammonia (lmol/L) 1.004 (1.002-1.006) <0.001 1.004 (1.002-1.006) <0.001 1.004 (1.002-1.006) <0.001
RRT 0.99 (0.64-1.51) 0.95 NA NA NA NA
IRRT NA NA 1.68 (1.04-2.72) 0.035 NA NA
CRRT NA NA NA NA 0.47 (0.26-0.82) 0.008
a 5 0.05.
*Model 1: n 5 822, 21-day spontaneous mortality 5 334, chi-square test 5 273, AUC of 0.82 (95% CI, 0.79-0.85).
†Model 2: n 5 822, 21-day spontaneous mortality 5 334, chi-square test 5 278, AUC of 0.82 (95% CI, 0.79-0.85).
‡Model 3: n 5 822, 21-day spontaneous mortality 5 334, chi-square test 5 281, AUC of 0.82 (95% CI, 0.80-0.85).
§Logistic regression.
Abbreviation: NA, not applicable.
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L of plasma per day (at 1-2 L per-hour rate) for 3 days
using 100% fresh frozen plasma. Whereas this technique
may resemble a subtype of IRRT, the composition of the
replacement fluid is different from the ones used in regu-
lar RRT sessions. Moreover, plasma exchange efficacy
may, in part, be attributed to a specific dampening effect
on the innate immune system response.
Previous studies have evaluated the effect of RRT
on hemodynamics in patients with ALF and acute kid-
ney injury. They have shown that, whereas IRRT use
has been associated with a significant reduction in car-
diac index and mean arterial pressure and a significant
increase in intracranial pressure, CRRT utilization has
not.(22,23) Consequently, CRRT was deemed safer
than IRRT in patients with ALF and risk of cerebral
edema. Therefore, CRRT use in patients with ALF
appears to improve hyperammonemia and reduce the
risk of cerebral edema and intracranial hypertension
while avoiding hemodynamic changes that may exacer-
bate intracranial pressure.
Using only a specific threshold of serum ammonia
to select patients for CRRT in this context might not
be enough, given lack of sensitivity observed. Never-
theless, a serum ammonia level 150-200 lmol/L has
been associated with increased risk of cerebral edema
and intracranial hypertension.(15) Although this study
was not designed nor powered to determine a thresh-
old serum ammonia value to stop CRRT, we would
advocate for the decision to cease CRRT be based on
further clinical data besides serum ammonia level (e.g.,
serum pH, bicarbonate, and potassium, urine output,
and fluid balance).
Taking into account pre-existent literature and our
findings, we suggest that patients with ALF and hyper-
ammonemia, especially those at greater risk for cerebral
edema and intracranial hypertension (e.g., with high-
grade HE, need for vasopressors, or with acute kidney
injury), should be considered for CRRT.(15,24)
Although serum ammonia modulation with CRRT
may impact positively ALF patients’ clinical outcomes,
this becomes only one more adjunctive therapeutic
strategy to control neurological failure. The timely
treatment of all organ failures in the intensive care unit
is of paramount importance and has contributed
greatly for the overall improvement of these patients’
clinical outcomes over the past decades.(6)
LIMITATIONS
This study had the following limitations that warrant
consideration. First, this was a retrospective cohort and
therefore may have been prone to selection bias. How-
ever, the large sample size, multicenter character, and
the use of data from prospectively enrolled patients
meeting entry criteria in the US-ALFSG registry may
have helped to minimize the risk of such bias.
Second, further details on RRT specifics were not
possible to obtain within the US-ALFSG registry. This
additional data may have added to the explanation of
RRT effect on ammonia dynamics and patients’ clinical
outcomes in ALF. Nevertheless, currently there is still
controversy regarding most technical aspects of RRT
use in general patients, including indications, early ver-
sus late initiation, intermittent versus continuous modes,
diffusion versus convection modes, predilution versus
postdilution fluid replacement, high versus low treat-
ment dose, and stopping rules.(12,18) For example, previ-
ous studies have shown that, among general critically ill
patients, diffusion and convection modes have similar
capacity for clearance of small molecules (e.g., urea, cre-
atinine, ammonia, and glutamine).(25) Furthermore,
high (35 mL/kg/h) and low (<35 mL/kg/h) dose of
renal replacement have been reported to have similar
effect on mortality and renal function recovery.(26) Even
if, in specific subgroups of patients, these technical
aspects may apply differently, the conclusions of such
studies help to strengthen the validity of our results.(27)
Despite these limitations, we believe that our find-
ings add to the previous literature on hyperammone-
mia and cerebral edema management in ALF. To
date, this is the largest multicenter study to evaluate
the effect of RRT on hyperammonemia in ALF. To
further study the use of RRT in this context, clinical
trials should be attempted in the near future. However,
this may prove to be a difficult task; not only is ALF a
rare disease, but also hyperammonemia may be difficult
to isolate from classical indications for RRT initiation
in the context of acute kidney injury.(12,27)
In a large cohort of patients with ALF, hyperammo-
nemia was associated with worse high-grade HE and
21-day post study admission TFS. Furthermore,
CRRT was associated with a reduction in serum
ammonia level and improved 21-day post study admis-
sion TFS. In ALF, CRRT may be an effective adjunc-
tive therapy to improve hyperammonemia as well as
overall clinical outcomes.
Appendix
Members and institutions participating in the Acute
Liver Failure Study Group 1998-2016 are as follows:
W.M. Lee, M.D. (Principal Investigator); Anne M.
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Larson, M.D., Iris Liou, M.D., University of
Washington, Seattle, WA; Oren Fix, M.D., Swedish
Medical Center, Seattle, WA; Michael Schilsky, M.D.,
Yale University, New Haven, CT; Timothy McCash-
land, M.D., University of Nebraska, Omaha, NE; J.
Eileen Hay, M.B.B.S., Mayo Clinic, Rochester, MN;
Natalie Murray, M.D., Baylor University Medical Cen-
ter, Dallas, TX; Obaid S. Shaikh, M.D., University of
Pittsburgh, Pittsburgh, PA; Andres Blei, M.D., North-
western University, Chicago, IL (deceased), Daniel
Ganger, M.D., Northwestern University, Chicago, IL;
Atif Zaman, M.D., University of Oregon, Portland, OR;
Steven H.B. Han, M.D., University of California, Los
Angeles, CA; Robert Fontana, M.D., University of
Michigan, Ann Arbor, MI; Brendan McGuire, M.D.,
University of Alabama, Birmingham, AL; Raymond T.
Chung, M.D., Massachusetts General Hospital, Boston,
MA; Alastair Smith, M.B., Ch.B., Duke University
Medical Center, Durham, NC; Robert Brown, M.D.,
Cornell/Columbia University, New York, NY; Jeffrey
Crippin, M.D., Washington University, St Louis, MO;
Edwin Harrison, M.D., Mayo Clinic, Scottsdale, AZ;
Adrian Reuben, M.B.B.S., Medical University of South
Carolina, Charleston, SC; Santiago Munoz, M.D., Albert
Einstein Medical Center, Philadelphia, PA; Rajender
Reddy, M.D., University of Pennsylvania, Philadelphia,
PA; R. Todd Stravitz, M.D., Virginia Commonwealth
University, Richmond, VA; Lorenzo Rossaro,M.D., Uni-
versity of California Davis, Sacramento, CA; Raj Satya-
narayana, M.D., Mayo Clinic, Jacksonville, FL; Tarek
Hassanein, M.D., University of California, San Diego,
CA; Constantine J. Karvellas MD, University of Alberta,
Edmonton, AB, Canada; Jodi Olson, M.D., University of
Kansas, Kansas City, KS; Ram Subramanian, M.D.,
Emory, Atlanta, GA; James Hanje, M.D., Ohio State
University, Columbus, OH; Bilal Hameed, M.D., Uni-
versity of California San Francisco, CA.
The University of Texas Southwestern Administrative
Group included Grace Samuel, Ezmina Lalani, Carla
Pezzia, and Corron Sanders, Ph.D., Nahid Attar, Linda
S. Hynan, Ph.D., and the Medical University of South
Carolina Data Coordination Unit included Valerie Dur-
kalski, Ph.D., Wenle Zhao, Ph.D., Jaime Speiser, Cath-
erine Dillon, Holly Battenhouse, and Michelle Gottfried.
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